跳至主要内容
临床试验/NCT05218564
NCT05218564Unknown不适用

Air as a Placebo: Increasing the Respiratory Performance of People With COPD Through Simple Expectations of Improvement. An Experimental, Randomised, Two-arm, Counterbalanced Study With Three Data Collection Sessions.

Fondazione Don Carlo Gnocchi Onlus1 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2020年2月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
102
试验地点
1
主要终点
Metres covered during 6 Minute Walking Test (6MWT)

研究概览

简要总结

COPD (Chronic Obstructive Pulmonary Disease) is a disease of the respiratory system characterised by irreversible airway obstruction of varying severity. The disease (known as COPD, Chronic Obstructive Pulmonary Disease) is progressive and is associated with a state of chronic inflammation of the lung tissue, which leads to a real remodelling of the bronchi causing a significant reduction in airway flow. Among the possible treatments, while the placebo is considered as an inert treatment, lacking any intrinsic therapeutic properties, there is evidence in the literature that not all placebos are equivalent and some are more effective than others, as for example in the case of migraine or osteoarthritis. The differences found between different types of placebos (e.g. oral, subcutaneous, intra-articular...) indicate that placebos are not inert but rather consist of multiple psychosocial elements that are part of the ritual of the therapeutic act. This is also the context for the studies by Lacasse et al. (for the International Nocturnal Oxygen (INOX) Research Group et al., 2017) and Jarosh et al., who investigated the effects of oxygen therapy both during sleep and during the course of daily life, studying its influences through the use of placebo in patients suffering from hypoxemia. However, in the literature, there are no studies investigating the role of oxygen (O2) during the performance of a test such as the Walking Test, otherwise known as the 6 Minute Walking Test (6MWT) compared with a placebo in patients with Chronic Obstructive Pulmonary Disease (COPD), nor whether the use of the latter would lead to comparable results.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Care Provider)

盲法说明

It is foreseen that the professional (Psychologist other than the one involved in the administration of the tests inherent to the assessment), once the patient has been identified, proposed the study and the readiness to manage the eventual episode of acute respiratory infection, and obtained his consent, will use the results of the above-mentioned system to assign the participant to one of the two groups and therefore to the order of conditions. In this way, the physiotherapist performing the planned treatment, the psychologist involved in administering the psychological assessment and the physician performing the respiratory function tests will be excluded from the randomisation process and blinded to the treatment.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who voluntarily agree to participate in the study;
  • Subjects with moderate-grade Chronic Obstructive Pulmonary Disease (COPD) (GOLD 2-50% ≤ FEV1 <80% of predicted) according to GOLD criteria;
  • Subjects undergoing treatment with oxygen therapy and non-smokers;
  • Ex-smokers
  • Outpatients and inpatients

排除标准

  • Refusal of Informed Consent
  • Severe cognitive impairment, detected by administration of the Mini Mental Status Examination Test (MMSE)
  • Pregnancy
  • Patients with oncological or psychiatric pathologies
  • Main immunodepression

研究组 & 干预措施

Group 1, consisting of participants with COPD and usually using O2

Experimental

In this group, in addition to the standard care, the participant undergoes the 6 Minute Walking Test (6MWT) using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The same, then, in addition to the standard care, is subjected to the execution of the 6 Minute Walking Test (6MWT), thanks to the use of cylinders of Oxygen (O2), believing that inside the cylinder there is Oxygen (O2). The sequence of this group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen).

干预措施: Compressed Medical Air (Other)

Group 2, consisting of participants with COPD and usually not using O2

Placebo Comparator

In this group, in addition to standard care, the participant is given the 6 Minute Walking Test (6MWT) using oxygen (O2) cylinders, believing that there is oxygen (O2) inside the cylinder. Next, the participant undergoes the 6 Minute Walking Test (6MWT), using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The sequence of this group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).

干预措施: Oxygen Therapy (Drug)

结局指标

主要结局

Metres covered during 6 Minute Walking Test (6MWT)

时间窗: Changes from baseline at the metres covered after the completion of the 6MWT performed using oxygen or compressed medical air. Up to 1 hour and half

Distance in metres during the 6 Minute Walking Test (6MWT)

次要结局

  • VAS Dyspnoea, measured by the British Medical Research Council's Modified Questionnaire (mMRC)(Change from baseline at the dyspnoea after the completion of the 6MWT performed using oxygen or compressed medical air. Up to 1 hour and half)
  • Saturation (SpO2)(Change from baseline at 3':30'' and at 6':00'' of the 6 Minute Walking Test (6MWT))
  • Feeling of fatigue, as measured by the Fatigue Severity Scale (FSS)(Changes from baseline at the FSS after the completion of the 6MWT performed using oxygen or compressed medical air. Up to 1 hour and half)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Paolo Banfi

Head of U.O.C. Cardio-Respiratory Rehabilitation

Fondazione Don Carlo Gnocchi Onlus

研究点 (1)

Loading locations...

相似试验